The latest announcement is out from Monopar Therapeutics Inc (MNPR).
Monopar Therapeutics Inc. has announced that Professor Rodney Hicks, a globally renowned radiopharmaceutical expert, will spearhead the Phase 1 dosimetry clinical trial of MNPR-101-Zr in advanced cancer patients. This move marks a significant step in the company’s efforts to advance its cancer treatment research.
See more data about MNPR stock on TipRanks’ Stock Analysis page.
